224 related articles for article (PubMed ID: 34672244)
1. Smoldering multiple myeloma: biology, clinical manifestations and management.
Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
[TBL] [Abstract][Full Text] [Related]
2. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
3. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
4. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
6. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Visram A; Cook J; Warsame R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
[TBL] [Abstract][Full Text] [Related]
7. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
Rajkumar SV; Bergsagel PL; Kumar S
Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
[TBL] [Abstract][Full Text] [Related]
8. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
[TBL] [Abstract][Full Text] [Related]
9. The consultant's guide to smoldering multiple myeloma.
Thorsteinsdottir S; Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
[TBL] [Abstract][Full Text] [Related]
10. How I approach smoldering multiple myeloma.
Vaxman I; Gertz MA
Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
13. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
14. Timing treatment for smoldering myeloma: is earlier better?
Hernández JÁ; Martínez-López J; Lahuerta JJ
Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
[TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
16. Smoldering multiple myeloma: Reviewing the rationale for intervention.
Gertz M
Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
[TBL] [Abstract][Full Text] [Related]
17. Smoldering multiple myeloma 40 years later: a story of unintended disease.
Yavorkovsky LL
Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
[No Abstract] [Full Text] [Related]
18. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
[TBL] [Abstract][Full Text] [Related]
19. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
[TBL] [Abstract][Full Text] [Related]
20. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]